The mammary gland sodium/iodide symporter (mgNIS)
乳腺钠/碘同向转运体 (mgNIS)
基本信息
- 批准号:7227544
- 负责人:
- 金额:$ 35.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-07-01 至 2009-04-30
- 项目状态:已结题
- 来源:
- 关键词:Active Biological TransportAdenocarcinomaAdverse effectsAnimal ModelApicalBiological AssayBreastBreast AdenocarcinomaCancer PatientCancerousCell LineCell membraneCellsCharacteristicsChemicalsComplementComplementary DNAEffectivenessEstrogensFine needle aspiration biopsyFlow CytometryFoundationsGastric GlandsGastric mucosaGene TransferHumanHuman MilkMalignant NeoplasmsMalignant neoplasm of thyroidMammary NeoplasmsMammary glandMediatingMembrane ProteinsMetastatic Neoplasm to the LungMolecular ChaperonesMusNeoplasm MetastasisOncogenesOxytocinPrimary NeoplasmProgesterone ReceptorsProlactinProtocols documentationRadiation therapyRegulationRoleSalivary GlandsSamplingTherapeuticThyroid GlandThyroid HormonesThyroid carcinomaTissuesTransgenic MiceVirusbreast cancer diagnosiscold temperaturehormone biosynthesishuman SLC5A5 proteinin vivomalignant breast neoplasmsodium-iodide symportersymportertumoruptake
项目摘要
DESCRIPTION (provided by applicant): The Na symporter (NIS) is a plasma membrane protein that mediates active I- transport in the thyroid and other tissues, including salivary glands, gastric mucosa, and lactating mammary glands (MG). NIS is regulated differently in each tissue. NIS-mediated I- transport in the thyroid is the first step in thyroid hormone biosynthesis. Endogenous functional expression of NIS in thyroid cancer is the foundation for the single most effective and most side effect-free anti-cancerous targeted radiation therapy available, i.e. radioiodide therapy, which has been successfully used in thyroid cancer for over 60 years. Our group isolated the cDNA encoding NIS and generated anti-NIS Abs. We have characterized thyroid NIS and its regulation. Mammary gland NIS (mgNIS) mediates active I- transport in lactating mammary cells, from which I- is passively translocated via a different transporter to the milk. mgNIS is expressed in lactating (but not in non-lactating) MG. mgNIS is regulated by estrogen, prolactin, and oxytocin. Mammary adenocarcinomas in transgenic mice display mgNIS-mediated active I- uptake. The only two cancers in which endogenous functional NIS is expressed are thyroid cancer and breast cancer. Over 80% of human breast cancers express mgNIS, but it is still unknown in what percentage of these NIS is functional. Normal non-lactating human breast samples do not express mgNIS. The endogenous expression of NIS in breast cancer provides an immense advantage over other cancers, into some of which NIS has been ectopically expressed by virus-mediated gene transfer. To characterize mgNIS in mammary cells and ascertain its potential value in breast cancer diagnosis and treatment, we propose: 1. a) To characterize the regulation of mgNIS in mammary cell lines; b) to investigate the effects of systemic and local regulatory factors on the expression of mgNIS in vivo; c) to determine whether low temperature and chemical chaperones promote targeting of mgNIS to the plasma membrane; d) to complement our understanding of I- translocation in the lactating mammary gland by assessing the role of putative apical I- transporters. 2) To develop a radioiodide therapeutic protocol and assess its effectiveness in the treatment of adenocarcinomas in animal models. 3) To ascertain, in fine needle aspirates from both human primary breast tumors and metastases, the functional expression of mgNIS and its possible correlation with other breast cancer parameters.
描述(由申请方提供):Na同向转运体(NIS)是一种质膜蛋白,介导甲状腺和其他组织(包括唾液腺、胃粘膜和泌乳乳腺(MG))中的主动I-转运。NIS在每个组织中的调节不同。NIS介导的甲状腺I-转运是甲状腺激素生物合成的第一步。NIS在甲状腺癌中的内源性功能表达是唯一最有效和最无副作用的抗癌靶向放射治疗的基础,即放射性碘治疗,其已成功地用于甲状腺癌超过60年。本课题组分离了NIS的cDNA并制备了抗NIS的Abs。我们的特点甲状腺NIS及其调节。乳腺NIS(mgNIS)介导泌乳乳腺细胞中的主动I-转运,I-通过不同的转运蛋白被动转运到乳汁中。mgNIS在哺乳期MG中表达(但在非哺乳期MG中不表达)。mgNIS受雌激素、催乳素和催产素调节。转基因小鼠中的乳腺癌显示mgNIS介导的主动I-摄取。仅有的两种表达内源性功能性NIS的癌症是甲状腺癌和乳腺癌。超过80%的人类乳腺癌表达mgNIS,但仍不清楚这些NIS的功能百分比。正常非哺乳期人乳腺样品不表达mgNIS。NIS在乳腺癌中的内源性表达提供了比其他癌症更大的优势,NIS通过病毒介导的基因转移异位表达到其中一些癌症中。为了表征乳腺细胞中的mgNIS,并确定其在乳腺癌诊断和治疗中的潜在价值,我们提出:1。a)表征乳腺细胞系中mgNIS的调节; B)研究体内全身和局部调节因子对mgNIS表达的影响; c)确定低温和化学分子伴侣是否促进mgNIS靶向质膜; d)通过评估推定的顶端I-转运蛋白的作用来补充我们对泌乳乳腺中I-易位的理解。2)建立一种放射性碘治疗方案,并评估其在动物模型中治疗腺癌的有效性。3)为了确定,在从人类原发性乳腺肿瘤和转移瘤的细针抽吸物中,mgNIS的功能表达及其与其他乳腺癌参数的可能相关性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nancy Carrasco其他文献
Nancy Carrasco的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nancy Carrasco', 18)}}的其他基金
2011 Mechanisms of Membrane Transport Gordon Research Conference
2011年膜传输机制戈登研究会议
- 批准号:
8128181 - 财政年份:2011
- 资助金额:
$ 35.23万 - 项目类别:
Molecular Characterization of the Sodium/lodide Symporter (NIS)
钠/碘同向转运体 (NIS) 的分子表征
- 批准号:
7990162 - 财政年份:2009
- 资助金额:
$ 35.23万 - 项目类别:
The mammary gland sodium/iodide symporter (mgNIS)
乳腺钠/碘同向转运体 (mgNIS)
- 批准号:
6763128 - 财政年份:2003
- 资助金额:
$ 35.23万 - 项目类别:
The mammary gland sodium/iodide symporter (mgNIS)
乳腺钠/碘同向转运体 (mgNIS)
- 批准号:
7078619 - 财政年份:2003
- 资助金额:
$ 35.23万 - 项目类别:
The mammary gland sodium/iodide symporter (mgNIS)
乳腺钠/碘同向转运体 (mgNIS)
- 批准号:
7267218 - 财政年份:2003
- 资助金额:
$ 35.23万 - 项目类别:
The mammary gland sodium/iodide symporter (mgNIS)
乳腺钠/碘同向转运体 (mgNIS)
- 批准号:
7115479 - 财政年份:2003
- 资助金额:
$ 35.23万 - 项目类别:
The mammary gland sodium/iodide symporter (mgNIS)
乳腺钠/碘同向转运体 (mgNIS)
- 批准号:
6917068 - 财政年份:2003
- 资助金额:
$ 35.23万 - 项目类别:
The mammary gland sodium/iodide symporter (mgNIS)
乳腺钠/碘同向转运体 (mgNIS)
- 批准号:
7433486 - 财政年份:2003
- 资助金额:
$ 35.23万 - 项目类别:
The mammary gland sodium/iodide symporter (mgNIS)
乳腺钠/碘同向转运体 (mgNIS)
- 批准号:
6679737 - 财政年份:2003
- 资助金额:
$ 35.23万 - 项目类别:
相似国自然基金
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
- 批准号:30840003
- 批准年份:2008
- 资助金额:12.0 万元
- 项目类别:专项基金项目
相似海外基金
Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
- 批准号:
478914 - 财政年份:2023
- 资助金额:
$ 35.23万 - 项目类别:
Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
- 批准号:
23K14913 - 财政年份:2023
- 资助金额:
$ 35.23万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
- 批准号:
23K15035 - 财政年份:2023
- 资助金额:
$ 35.23万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
- 批准号:
10657069 - 财政年份:2023
- 资助金额:
$ 35.23万 - 项目类别:
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
- 批准号:
10442874 - 财政年份:2023
- 资助金额:
$ 35.23万 - 项目类别:
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
- 批准号:
23H02698 - 财政年份:2023
- 资助金额:
$ 35.23万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
- 批准号:
23K08326 - 财政年份:2023
- 资助金额:
$ 35.23万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
- 批准号:
23K14614 - 财政年份:2023
- 资助金额:
$ 35.23万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
- 批准号:
23K15075 - 财政年份:2023
- 资助金额:
$ 35.23万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
- 批准号:
10743611 - 财政年份:2023
- 资助金额:
$ 35.23万 - 项目类别:














{{item.name}}会员




